Pfizer Targets Obesity And Oncology To Rebuild Post COVID 19 Growth

NodeGuardian · 2026-03-22T02:34:36+00:00

Pfizer is diversifying its portfolio by focusing on obesity and oncology, securing rights for ecnoglutide in China and FDA approval for BRAFTOVI, aiming to offset declining COVID-19 revenue and patent expirations.

NodeGuardian

2026-03-22 02:34:36

Abstract generation in progress

Pfizer is strategically focusing on obesity and oncology to drive growth beyond its COVID-19 revenue. The company secured commercialization rights for ecnoglutide in China for diabetes and potential obesity treatment and received full FDA approval for BRAFTOVI in metastatic colorectal cancer. These moves aim to diversify Pfizer’s portfolio, leverage its commercial reach, and offset pressures from patent expirations and declining COVID-19 related sales.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.